<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>RESEARCH COUNCILS UK SUBMISSION TO THE HOUSE OF COMMONS SCIENCE AND TECHNOLOGY COMMITTEE INQUIRY ON ANTIMICROBIAL RESISTANCE</title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><h2 style="margin:0pt; page-break-after:avoid; page-break-inside:avoid; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Research Councils </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">UK </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0012)</span></h2><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Research Councils UK (RCUK) is a strategic partnership set up to champion the research supported by the seven UK Research Councils. RCUK was established to enable the Councils to work together more effectively to enhance the overall impact and effectiveness of their research, training and innovation activities, and contributing to the delivery of the Government’s objectives for science and innovation.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">This response is submitted by RCUK </span><span style="font-family:'Times New Roman'; font-size:11pt">on behalf of the following research c</span><span style="font-family:'Times New Roman'; font-size:11pt">ouncils:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:24.93pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Biotechnology and Biological Sciences Research Council (BBSRC)</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:24.93pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Economic and Social</span><span style="font-family:'Times New Roman'; font-size:11pt"> Research Council (ESRC)</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:24.93pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Engineering and Physical Sciences Research Council (EPSRC)</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:24.93pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Medical Research Council (MRC)</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:24.93pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Science and Technology Facilities Council (STFC)</span></li></ul><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance has been of growing concern to RCUK for the past few years and we are encouraged that the profile has been raised at the highest levels.  </span><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the opportunity to provide evidence to the Committee and have focuse</span><span style="font-family:'Times New Roman'; font-size:11pt">d on those questions that fall within our combined remit and expertise.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">4.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The</span><span style="font-family:'Times New Roman'; font-size:11pt"> challenges raised by antimicrobial resistance require a broad approach</span><span style="font-family:'Times New Roman'; font-size:11pt">. This approach should</span><span style="font-family:'Times New Roman'; font-size:11pt"> encompass new therapeutic agents</span><span style="font-family:'Times New Roman'; font-size:11pt">, alternative strategies for controlling disease</span><span style="font-family:'Times New Roman'; font-size:11pt">, diagnostics, surveillance, modelling, transmission dynamics</span><span style="font-family:'Times New Roman'; font-size:11pt"> as well as health systems</span><span style="font-family:'Times New Roman'; font-size:11pt">, behaviour change</span><span style="font-family:'Times New Roman'; font-size:11pt"> and implementation -all</span><span style="font-family:'Times New Roman'; font-size:11pt"> built on strong underpinning biology of the organisms and the hosts.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">5.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The research councils</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">broad </span><span style="font-family:'Times New Roman'; font-size:11pt">remit</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">allow support </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">address antimicrobial resistance across the whole of the research </span><span style="font-family:'Times New Roman'; font-size:11pt">spectrum</span><span style="font-family:'Times New Roman'; font-size:11pt">. However, the level of activity needed to address this issue can only be achieved through collaborative working, bringing together disciplines in a coordinated way.  This will require a coordinated response between the research councils</span><span style="font-family:'Times New Roman'; font-size:11pt">, government departments, </span><span style="font-family:'Times New Roman'; font-size:11pt">other research funders in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> and industry</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Response</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the gaps in our knowledge about antimicrobial resistance? </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">6.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance has been of growing concern to RCUK for the past few years and the research councils have identified a number of gaps and areas of research need. Activities that have helped inform priorities include an MRC </span><span style="font-family:'Times New Roman'; font-size:11pt">meeting</span><span style="font-family:'Times New Roman'; font-size:11pt"> in July 2013 </span><span style="font-family:'Times New Roman'; font-size:11pt">to identify </span><span style="font-family:'Times New Roman'; font-size:11pt">research </span><span style="font-family:'Times New Roman'; font-size:11pt">needs in this area</span><span style="font-family:'Times New Roman'; font-size:11pt"> and joint research council work</span><span style="font-family:'Times New Roman'; font-size:11pt"> with the Wellcome Trust to investigate why there has been a lack of development in the pharma pipeline</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and with EU partners to identify gaps and opportunities. </span><span style="font-family:'Times New Roman'; font-size:11pt">Also, in February 2013 STFC and the Royal United Services Institute (RUSI) organised a workshop looking at gaps in research knowledge resulting in an RUSI </span><span style="font-family:'Times New Roman'; font-size:11pt">Occasional Paper, “Tackling Antimicrobial Resistance: Identifying Future Research Themes”</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">7.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The ESRC is monitoring closely the current NIHR themed call in antimicrobial resistance with a view to determining any future research needs in the social and behavioural sciences.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">8.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">It is clear that across the UK there is expertise in a range of </span><span style="font-family:'Times New Roman'; font-size:11pt">disciplines that could be brought to bear on the </span><span style="font-family:'Times New Roman'; font-size:11pt">following </span><span style="font-family:'Times New Roman'; font-size:11pt">issues:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> deep mechanistic understanding of the </span><span style="font-family:'Times New Roman'; font-size:11pt">basic biology </span><span style="font-family:'Times New Roman'; font-size:11pt">of the </span><span style="font-family:'Times New Roman'; font-size:11pt">organisms is paramount</span><span style="font-family:'Times New Roman'; font-size:11pt">. The continuation of</span><span style="font-family:'Times New Roman'; font-size:11pt"> strong support for basic microbiology research </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> essential. </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Greater</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">understanding</span><span style="font-family:'Times New Roman'; font-size:11pt"> should be developed</span><span style="font-family:'Times New Roman'; font-size:11pt">– both genetic and mechanistic -</span><span style="font-family:'Times New Roman'; font-size:11pt"> of how organisms become resistant.  </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Greater understanding is needed of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> mechanisms and spread of resistance which </span><span style="font-family:'Times New Roman'; font-size:11pt">should </span><span style="font-family:'Times New Roman'; font-size:11pt">include surveillance and monitoring of resistant strains</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The spread of antibacterial resista</span><span style="font-family:'Times New Roman'; font-size:11pt">nce has </span><span style="font-family:'Times New Roman'; font-size:11pt">increased rapidly,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">nationally and globally. We will need </span><span style="font-family:'Times New Roman'; font-size:11pt">a multidisciplinary approach </span><span style="font-family:'Times New Roman'; font-size:11pt">to understand the dynamics of the transmission of these </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">genes and</span><span style="font-family:'Times New Roman'; font-size:11pt"> also the</span><span style="font-family:'Times New Roman'; font-size:11pt"> bacteria </span><span style="font-family:'Times New Roman'; font-size:11pt">themselves </span><span style="font-family:'Times New Roman'; font-size:11pt">to design preventive measures for controlling resistance. </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We need a deeper understanding of how the host and the organism interact – </span><span style="font-family:'Times New Roman'; font-size:11pt">and the subsequent </span><span style="font-family:'Times New Roman'; font-size:11pt">host response to infection.  This </span><span style="font-family:'Times New Roman'; font-size:11pt">will underpin development of</span><span style="font-family:'Times New Roman'; font-size:11pt"> new treatment</span><span style="font-family:'Times New Roman'; font-size:11pt"> and prevention strategies such as vaccines and</span><span style="font-family:'Times New Roman'; font-size:11pt"> immunotherapies.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Development of reliable, high throughput and rapid diagnostic systems</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Monitoring and tracking of resistance and resistant strains globally</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Innovation in bioprocessing which, coupled with greater biological understanding as described above, will enable the development of cheaper, more effective combination therapies.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 46.61pt; padding-left:25.39pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Using the insights of behavioural economics and other social sciences to change prescribing behaviours and patient expectations</span></li></ul></ul><p style="margin:0pt 0pt 0pt 72pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This is not an exhaustive list - there are a range of research areas across the councils that could impact antimicrobial resistance.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">9.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Antibacterial resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">is also an important issue for a</span><span style="font-family:'Times New Roman'; font-size:11pt">nimal</span><span style="font-family:'Times New Roman'; font-size:11pt"> health – from </span><span style="font-family:'Times New Roman'; font-size:11pt">an animal health, welfare and production perspective </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">also </span><span style="font-family:'Times New Roman'; font-size:11pt">concerns </span><span style="font-family:'Times New Roman'; font-size:11pt">around </span><span style="font-family:'Times New Roman'; font-size:11pt">the potential risk to humans of antibiotic resistance in zoonotic organisms (although the EU has banned all non-therapeutic use of antibiotics). </span><span style="font-family:'Times New Roman'; font-size:11pt">There is a gap in our understanding of the extent to which </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> arises from animal sources versus hum</span><span style="font-family:'Times New Roman'; font-size:11pt">ans, and the extent to which antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> (specifically antibiotic resistance) has been transferred from animals (see, for example, recent studies on the origins of MRSA</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt">). Further work on how changes in farm business models impact use of antibiotics would also be helpful.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">10.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition to antibacterial resistance, </span><span style="font-family:'Times New Roman'; font-size:11pt">the issue of anthelminthic resistance is a major problem for the farming industry.  Anthelminthics are used to treat helminth parasites and protozoa infestation in ruminants, pigs and poultry and unlike antibiotics there are only </span><span style="font-family:'Times New Roman'; font-size:11pt">three </span><span style="font-family:'Times New Roman'; font-size:11pt">major families of an</span><span style="font-family:'Times New Roman'; font-size:11pt">thelmintic drugs</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">W</span><span style="font-family:'Times New Roman'; font-size:11pt">idespread resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> to these drugs has been</span><span style="font-family:'Times New Roman'; font-size:11pt"> reported in most UK sheep farms.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">11.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Advances in </span><span style="font-family:'Times New Roman'; font-size:11pt">disease surveillance and </span><span style="font-family:'Times New Roman'; font-size:11pt">point-of-care diagnostics, and particularly the application of rapid whole genome sequencing, are likely to change the antimicrobial market over the next 10-15 years. Molecular diagnostic tools can also be used to track the spread of resistant organisms and identify if an organism has become resistant to a particular treatment.  </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">12.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Currently</span><span style="font-family:'Times New Roman'; font-size:11pt">, however, development of reliable, high throughput and rapid diagnostic systems, ideally capable of operating successfully in a clinical rather than laboratory environment remains</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">a significant gap</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">esearch challenges </span><span style="font-family:'Times New Roman'; font-size:11pt">here </span><span style="font-family:'Times New Roman'; font-size:11pt">include</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">data mining for biomarker d</span><span style="font-family:'Times New Roman'; font-size:11pt">iscovery,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">advanced</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">nanomaterials, microfluidics, sensor systems,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">microelectronics</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">telecommunications. For disease surveillance there are big data research challenges</span><span style="font-family:'Times New Roman'; font-size:11pt"> to be addressed such as</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">innov</span><span style="font-family:'Times New Roman'; font-size:11pt">ative web-tracking technologies and</span><span style="font-family:'Times New Roman'; font-size:11pt"> mathematical modelling of epidemics.  </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">13.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he </span><span style="font-family:'Times New Roman'; font-size:11pt">research councils</span><span style="font-family:'Times New Roman'; font-size:11pt">, often in partnership with the Technology Strategy </span><span style="font-family:'Times New Roman'; font-size:11pt">Board (</span><span style="font-family:'Times New Roman'; font-size:11pt">TSB)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">are</span><span style="font-family:'Times New Roman'; font-size:11pt"> invest</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> in a number</span><span style="font-family:'Times New Roman'; font-size:11pt"> of projects to develop and test novel diagnostic</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">.  For example, EPSRC has recently established an </span><span style="font-family:'Times New Roman'; font-size:11pt">£11</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">illion</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">interdisciplinary research centre in University College London to create a new generation of early-warning sensing systems for diagnosis, monitoring </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">prevention of the spread of infectious diseases.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">MRC has worked in partnership with TSB to fund </span><span style="font-family:'Times New Roman'; font-size:11pt">research on </span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt"> detection and </span><span style="font-family:'Times New Roman'; font-size:11pt">identification </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">infectious agents</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Despite this investment</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">diagnostics</span><span style="font-family:'Times New Roman'; font-size:11pt"> remains priority area for the field.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">14.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The MRC, on behalf of </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">research councils and </span><span style="font-family:'Times New Roman'; font-size:11pt">biomedical research </span><span style="font-family:'Times New Roman'; font-size:11pt">funders, has been working with colleagues</span><span style="font-family:'Times New Roman'; font-size:11pt"> from EU member and accession states</span><span style="font-family:'Times New Roman'; font-size:11pt"> on a Joint Programming Initiative </span><span style="font-family:'Times New Roman'; font-size:11pt">on </span><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial Resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">.  As part of this</span><span style="font-family:'Times New Roman'; font-size:11pt"> activity</span><span style="font-family:'Times New Roman'; font-size:11pt">, a strategic research agenda </span><span style="font-family:'Times New Roman'; font-size:11pt">is being developed</span><span style="font-family:'Times New Roman'; font-size:11pt"> and is due to be </span><span style="font-family:'Times New Roman'; font-size:11pt">launched in March 2014.  This will highlight a range of gaps and opportunities to be addressed through international cooperation.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The research agenda will be broad encompassing scientific, societal and environmental challenges.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified? </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">15.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In May 2013 </span><span style="font-family:'Times New Roman'; font-size:11pt">BBSRC, MRC and the Wellcome Trust </span><span style="font-family:'Times New Roman'; font-size:11pt">supported </span><span style="font-family:'Times New Roman'; font-size:11pt">a one day symposium ‘Lessons to be learnt from Pharma about drug discovery and development of new antibacterial drugs’</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> organised by Antibiotic Action.  The </span><span style="font-family:'Times New Roman'; font-size:11pt">report</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">noted that: </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:2.7pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">‘New antibiotic development has slowed alarmingly in recent decades, and the antibiotic development pipeline is poorly stocked. This lack of activity reflects ‘market failure’ – pharmaceutical companies have retreated from antibiotic development as the risk–reward ratio has been considered unattractive’.  </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">16.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The supply pipeline of new therapeutic agents is seen by many as a commercial </span><span style="font-family:'Times New Roman'; font-size:11pt">issue </span><span style="font-family:'Times New Roman'; font-size:11pt">but d</span><span style="font-family:'Times New Roman'; font-size:11pt">irected R&amp;D </span><span style="font-family:'Times New Roman'; font-size:11pt">in partnership with</span><span style="font-family:'Times New Roman'; font-size:11pt"> the research councils </span><span style="font-family:'Times New Roman'; font-size:11pt">could increase the efficiency of the se</span><span style="font-family:'Times New Roman'; font-size:11pt">arch for new therapeutic agents, </span><span style="font-family:'Times New Roman'; font-size:11pt">identif</span><span style="font-family:'Times New Roman'; font-size:11pt">ication of</span><span style="font-family:'Times New Roman'; font-size:11pt"> new ones</span><span style="font-family:'Times New Roman'; font-size:11pt"> and improved the development processes for getting to market</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">17.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">However, the major impediment to drug discovery is the </span><span style="font-family:'Times New Roman'; font-size:11pt">current</span><span style="font-family:'Times New Roman'; font-size:11pt"> economic model which makes private sector investment by large pharmaceutical companies less attractive in this area than many others (e.g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> chemotherapy and treatments for long term degenerative disorders)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> There are discussions around </span><span style="font-family:'Times New Roman'; font-size:11pt">changing the </span><span style="font-family:'Times New Roman'; font-size:11pt">business models to make discovery more attractive for industry partners</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> research into new business models</span><span style="font-family:'Times New Roman'; font-size:11pt"> could be taken forward </span><span style="font-family:'Times New Roman'; font-size:11pt">by the ESRC </span><span style="font-family:'Times New Roman'; font-size:11pt">and/</span><span style="font-family:'Times New Roman'; font-size:11pt">or TSB.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">18.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The level of investment from the pharma</span><span style="font-family:'Times New Roman'; font-size:11pt">ceutical</span><span style="font-family:'Times New Roman'; font-size:11pt"> industry will need to be addressed by that sector.  However, </span><span style="font-family:'Times New Roman'; font-size:11pt">BBSRC, EPSRC and the MRC</span><span style="font-family:'Times New Roman'; font-size:11pt"> all</span><span style="font-family:'Times New Roman'; font-size:11pt"> invest significantly in </span><span style="font-family:'Times New Roman'; font-size:11pt">research on basic </span><span style="font-family:'Times New Roman'; font-size:11pt">microbiology</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">on </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2011/2012 the MRC, BBSRC and EPSRC invested approximately £</span><span style="font-family:'Times New Roman'; font-size:11pt">19.6</span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> in antimicrobial resistance research</span><span style="font-family:'Times New Roman'; font-size:11pt">. This excludes </span><span style="font-family:'Times New Roman'; font-size:11pt">major</span><span style="font-family:'Times New Roman'; font-size:11pt"> investments into the underpinning basic biology of the organisms or the hosts. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, EPSRC’s investment includes developing epidemiological models of infectious diseases, techniques to diagnose and monitor infectious diseases and novel antimicrobial therapeutics/agents in response to drug resistance.  </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">19.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In terms of investment directly into developing new antibiotics or treatments, </span><span style="font-family:'Times New Roman'; font-size:11pt">there has been major investment by the European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) through the Innovative Medicines Initiative</span><span style="font-family:'Times New Roman'; font-size:11pt"> (IMI)</span><span style="font-family:'Times New Roman'; font-size:11pt">. To date, </span><span style="font-family:'Times New Roman'; font-size:11pt">the Commission and EFPIA</span><span style="font-family:'Times New Roman'; font-size:11pt"> have jointly committed €</span><span style="font-family:'Times New Roman'; font-size:11pt">431m </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">five </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR consortia - </span><span style="font-family:'Times New Roman'; font-size:11pt">approximately a quarter of all IMI research commitment.</span><span style="font-family:'Times New Roman'; font-size:11pt">  The MRC is the BIS appointed UK representative on the State Representative Group for the IMI.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">20.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There is </span><span style="font-family:'Times New Roman'; font-size:11pt">a broad </span><span style="font-family:'Times New Roman'; font-size:11pt">recognition that the purely genomic approach used by some pharma</span><span style="font-family:'Times New Roman'; font-size:11pt">ceutical companies</span><span style="font-family:'Times New Roman'; font-size:11pt"> to identify new targets over the past 10 years has not yielded results.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The research councils consider that a</span><span style="font-family:'Times New Roman'; font-size:11pt"> more holistic approach is needed to better understand cellular mechanisms, identify putative targets through genomics but couple this with whole-cell based assays and better animal models. </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">21.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he</span><span style="font-family:'Times New Roman'; font-size:11pt"> researc</span><span style="font-family:'Times New Roman'; font-size:11pt">h councils recognise that there</span><span style="font-family:'Times New Roman'; font-size:11pt"> is much </span><span style="font-family:'Times New Roman'; font-size:11pt">they</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">can do to </span><span style="font-family:'Times New Roman'; font-size:11pt">support </span><span style="font-family:'Times New Roman'; font-size:11pt">drug discovery and development</span><span style="font-family:'Times New Roman'; font-size:11pt"> at earlier stages</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">mproved target identification and validation </span><span style="font-family:'Times New Roman'; font-size:11pt">is needed </span><span style="font-family:'Times New Roman'; font-size:11pt">with</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">better</span><span style="font-family:'Times New Roman'; font-size:11pt"> screening to ensure that putative targets are “druggable” and </span><span style="font-family:'Times New Roman'; font-size:11pt">that </span><span style="font-family:'Times New Roman'; font-size:11pt">attacking the target will effectively kill the organism.  This should also include </span><span style="font-family:'Times New Roman'; font-size:11pt">screening for resistance at the earliest stages.  Research should continue on proven targets as </span><span style="font-family:'Times New Roman'; font-size:11pt">well as </span><span style="font-family:'Times New Roman'; font-size:11pt">identifying new </span><span style="font-family:'Times New Roman'; font-size:11pt">targets</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">22.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">New</span><span style="font-family:'Times New Roman'; font-size:11pt"> approaches might include the application of novel chemistry to discover new targets, to manipulate current drugs to prevent resistance, and to potentially rescue old compounds which have not reached the clinic due to toxicity or lack of efficacy.  In addition to novel chemistry, synthetic biology can create novel advantageous analogues of known antibiotics and apply structure-informed de novo drug-design to overcome resistance mechanisms, toxicity issues and, importantly to ensure that drugs are able to enter the organisms.  </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">23.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There also remains a large untapped resource of microbial, plant and animal sources and underexplored environmental niches </span><span style="font-family:'Times New Roman'; font-size:11pt">that may </span><span style="font-family:'Times New Roman'; font-size:11pt">yield novel molecules and scaffolds on which to base new antibiotics.  Exploration of these sources in a thorough and </span><span style="font-family:'Times New Roman'; font-size:11pt">co-ordinated way may offer new treatments for infectious diseases.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">24.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">pportunities exist for disease control strategies that avoid the use of antimicrobial drugs/agents </span><span style="font-family:'Times New Roman'; font-size:11pt">such as the developing novel vaccines, </span><span style="font-family:'Times New Roman'; font-size:11pt">including ve</span><span style="font-family:'Times New Roman'; font-size:11pt">terinary vaccines, against bacterial infection or immunotherapies for the bacteria or the toxins they produce.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">25.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">More broadly </span><span style="font-family:'Times New Roman'; font-size:11pt">the control and transmission of infection is effected via </span><span style="font-family:'Times New Roman'; font-size:11pt">people, </span><span style="font-family:'Times New Roman'; font-size:11pt">surfaces, interfaces and materials (including those within medical devices</span><span style="font-family:'Times New Roman'; font-size:11pt">, dressings etc.</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">that </span><span style="font-family:'Times New Roman'; font-size:11pt">come into contact with </span><span style="font-family:'Times New Roman'; font-size:11pt">other </span><span style="font-family:'Times New Roman'; font-size:11pt">humans, animals and the environment. Opportunities exist for frontier </span><span style="font-family:'Times New Roman'; font-size:11pt">r</span><span style="font-family:'Times New Roman'; font-size:11pt">esearch at the interface between advanced materials, engineering sciences, modelling, pharmaceutical sciences, life </span><span style="font-family:'Times New Roman'; font-size:11pt">sciences</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">behavioural and </span><span style="font-family:'Times New Roman'; font-size:11pt">clinical </span><span style="font-family:'Times New Roman'; font-size:11pt">science</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">26.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">It is the research council</span><span style="font-family:'Times New Roman'; font-size:11pt">s’</span><span style="font-family:'Times New Roman'; font-size:11pt"> view that development and front-line deployment of a viable and cost effective means of addressing the challenge requires a broad focus encompassing new therapeutic agents</span><span style="font-family:'Times New Roman'; font-size:11pt">, alternative strategies for controlling disease</span><span style="font-family:'Times New Roman'; font-size:11pt">, diagnostics, surveillance, modelling, transmission dynamics</span><span style="font-family:'Times New Roman'; font-size:11pt">, health care systems and behaviour change all</span><span style="font-family:'Times New Roman'; font-size:11pt"> built on strong underpinning biology of the organisms and the hosts.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">27.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">his </span><span style="font-family:'Times New Roman'; font-size:11pt">level of </span><span style="font-family:'Times New Roman'; font-size:11pt">activity </span><span style="font-family:'Times New Roman'; font-size:11pt">can only</span><span style="font-family:'Times New Roman'; font-size:11pt"> be achieved through collaborative working, bringing together disciplines </span><span style="font-family:'Times New Roman'; font-size:11pt">and sectors </span><span style="font-family:'Times New Roman'; font-size:11pt">in a coordinated </span><span style="font-family:'Times New Roman'; font-size:11pt">way.  This will require a coordinated response between the </span><span style="font-family:'Times New Roman'; font-size:11pt">research councils </span><span style="font-family:'Times New Roman'; font-size:11pt">and other funders in the UK as well as industry.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">28.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Research will also need to cross human/animal boundaries. </span><span style="font-family:'Times New Roman'; font-size:11pt">Multidisciplinary collaborations between researchers working on AMR in organisms present in humans, animals and the environment under a ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">one health’ approach is important to the strategy for investment in AMR research. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">29.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Global coordination will be requ</span><span style="font-family:'Times New Roman'; font-size:11pt">ired for a number of activities.  For example, detection and monitoring, both nationally and internationally, of the emergence and spread of both new diseases and new antibiotic strains of existing disease-causing organisms.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This could also cover </span><span style="font-family:'Times New Roman'; font-size:11pt">surveillance of </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance strains and transmission dynamics</span><span style="font-family:'Times New Roman'; font-size:11pt"> of resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">.  The UK has been actively engaged, along with a number of other countries, in the International Severe Acute Respiratory Infections Consortium.  This has established a global network of networks to monitor respiratory infections globally and could serve as a model for antimicrobial resistance monitoring.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">30.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In terms of coordinating research, the UK, represented through the MRC, has </span><span style="font-family:'Times New Roman'; font-size:11pt">on</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">going participation in the Joint</span><span style="font-family:'Times New Roman'; font-size:11pt"> Programming Initiative</span><span style="font-family:'Times New Roman'; font-size:11pt"> on Antimicrobial Resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">.  This aims </span><span style="font-family:'Times New Roman'; font-size:11pt">to streamline the European research efforts in </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> by joint planning, implementation and evaluation of national research programmes.</span><span style="font-family:'Times New Roman'; font-size:11pt">  This will lead to the launch of an interdisciplinary research agenda and other research councils will be invited to partner initiatives within their respective fields.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">31.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK has also worked with </span><span style="font-family:'Times New Roman'; font-size:11pt">Canadian Institute of Health Research</span><span style="font-family:'Times New Roman'; font-size:11pt"> (CIHR)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">to set up research collaborations across the two countries directly focussed on antimicrobial resistance. Two consortia are currently funded</span><span style="font-family:'Times New Roman'; font-size:11pt"> by the MRC and </span><span style="font-family:'Times New Roman'; font-size:11pt">CIHR</span><span style="font-family:'Times New Roman'; font-size:11pt">, totalling </span><span style="font-family:'Times New Roman'; font-size:11pt">£4m.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">32.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">BBSRC is a partner in the Global Strategic Alliance for the Coordination of Research on the Major Infectious Diseases of Animals and Zoonoses</span><span style="font-family:'Times New Roman'; font-size:11pt">. The Alliance</span><span style="font-family:'Times New Roman'; font-size:11pt"> is considering </span><span style="font-family:'Times New Roman'; font-size:11pt">alternatives to antimicrobials and </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial resistance as a cross-cutting strategic theme</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">33.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Government</span><span style="font-family:'Times New Roman'; font-size:11pt">’s</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">strategy </span><span style="font-family:'Times New Roman'; font-size:11pt">has shown an inclusive approach and highlights a number of key areas for a range of stakeholders to engage with.  It provides a </span><span style="font-family:'Times New Roman'; font-size:11pt">global</span><span style="font-family:'Times New Roman'; font-size:11pt"> perspective and promotes interdisciplinary research, with a call to address some challenging areas of research. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">34.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We recognise that the action plan is primarily focused on antibacterial resistance as this is the most significant problem for humans. The links with the </span><span style="font-family:'Times New Roman'; font-size:11pt">C</span><span style="font-family:'Times New Roman'; font-size:11pt">hief </span><span style="font-family:'Times New Roman'; font-size:11pt">V</span><span style="font-family:'Times New Roman'; font-size:11pt">eterinary </span><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">fficer are strong and we welcome the recommendations made.  However, the strategy could have given more </span><span style="font-family:'Times New Roman'; font-size:11pt">emphasis to disease prevention strategies such as vaccination, especially in animals, as this would reduce antibiotic use.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:Verdana; font-size:11pt; font-weight:normal">35.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Potential weaknesses may include </span><span style="font-family:'Times New Roman'; font-size:11pt">lack of mention</span><span style="font-family:'Times New Roman'; font-size:11pt"> of knowledge exchange, especially as research</span><span style="font-family:'Times New Roman'; font-size:11pt"> encouraged by the strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> will be </span><span style="font-family:'Times New Roman'; font-size:11pt">highly </span><span style="font-family:'Times New Roman'; font-size:11pt">interdisciplinary.</span><span style="font-family:'Times New Roman'; font-size:11pt">  Also, the implementation will need to be addressed.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Plans for this</span><span style="font-family:'Times New Roman'; font-size:11pt"> are discussed in the strategy however the research councils would welcome involvement </span><span style="font-family:'Times New Roman'; font-size:11pt">at all levels to </span><span style="font-family:'Times New Roman'; font-size:11pt">help </span><span style="font-family:'Times New Roman'; font-size:11pt">ensure a joined up approach.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="font-family:'Times New Roman'; font-size:10pt">Further details are available at </span><a href="http://www.rcuk.ac.uk"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; text-decoration:underline">www.rcuk.ac.uk</span></a><span style="font-family:'Times New Roman'; font-size:10pt"> </span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Arial; font-size:8pt"> Cole, J (ed). 2013. Tackling Antimicrobial Resistance: Identifying Future Themes. STFC/RUSI Occasional Paper. </span><span style="font-family:Arial; font-size:8pt">(</span><a href="http://www.rusi.org/publications/occasionalpapers/ref:O521C7E982D06B/"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.rusi.org/publications/occasionalpapers/ref:O521C7E982D06B/</span></a><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">)</span><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Arial; font-size:8pt"> Spoor LE, McAdam PR, Weinert LA, Rambaut A, Hasman H, Aarestrup FM, Kearns AM, Larsen AR, Skov RL, Fitzgerald JR. 2013. Livestock origin for a human pandemic clone of community-associated methicillin-resistant </span><span style="font-family:Arial; font-size:8pt; font-style:italic">Staphylococcus aureus</span><span style="font-family:Arial; font-size:8pt">. mBio 4(4):e00356-13. doi:10.1128/mBio.00356-13.</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Arial; font-size:8pt"> </span><a href="http://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Arial; font-size:8pt"> £6.3m BBSRC, £4.8m MRC, £8.5m EPSRC</span></p></body></html>